skip to content

FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD)

Investors

Investor updates
view all

stay updated

get the latest news and updates to your inbox.